EGFR-TKIs Combine Chemotherapy as First-line Therapy for Patients With Advanced EGFR Mutation-positive NSCLC

NCT02886195 · clinicaltrials.gov ↗

PHASE3

Phase

UNKNOWN

Status

120

Enrollment

OTHER_GOV

Sponsor class

Conditions

EGFR Gene Mutation

Interventions

DRUG: pemetrexed
DRUG: cisplatin
DRUG: Erlotinib

Sponsor

Fujian Cancer Hospital